Journal
CLINICAL AND EXPERIMENTAL MEDICINE
Volume 18, Issue 1, Pages 45-50Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s10238-017-0463-4
Keywords
Liver fibrosis; HCV; ELF; TE-FibroScan; HA; PIIINP; TIMP-1
Categories
Funding
- Science and Technology Development Fund (STDF), Egypt Grant Basic and applied research [5380]
Ask authors/readers for more resources
Evaluation of liver fibrosis stage is crucial in the assessment of chronic HCV patients, regarding decision to start treatment and during follow-up. Our aim was to assess the validity of the enhanced liver fibrosis (ELF) score in discrimination of advanced stage of liver fibrosis in na < ve chronic HCV patients. We prospectively evaluated liver fibrosis stage in one hundred eighty-one na < ve chronic HCV Egyptian patients by transient elastography (TE)-FibroScan. Patients were categorized into mild to moderate fibrosis (F2) group and advanced fibrosis (F3) group. The ELF score components, hyaluronic acid (HA), amino-terminal propeptide of type-III-procollagen (PIIINP) and tissue inhibitor of metalloproteinase type-1 (TIMP-1), were done using ELISA test. The mean values of ELF and its individual components significantly correlated with the hepatic fibrosis stage as measured by TE-FibroScan (P value 0.001). ELF cutoff value of 9.8 generated a sensitivity of 77.8%, specificity of 67.1%, area under the receiver operator characteristic curve (AUROC) of 0.76 with 95% confidence interval [CI] (0.68-0.83) for detecting advanced fibrosis (F 3). ELF panel is a good, reliable noninvasive test and showed comparable results to TE-FibroScan in detecting liver fibrosis stage in treatment na < ve chronic HCV patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available